Elevated Expression of EPHA2 Is Associated With Poor Prognosis After Radical Prostatectomy in Prostate Cancer

Background/Aim: Therapeutic targeting of receptor protein tyrosine kinases (PTKs) has proven successful in treating cancer. However, reports about PTKs in treating prostate cancer are few. Elevated expression of the erythropoietin-producing hepatocellular receptor A2 (EPHA2) receptor tyrosine kinase, a transmembrane protein, is associated with poor prognosis of certain cancer types when the enzyme is dephosphorylated. This study investigated whether EPHA2 is useful in predicting the biochemical recurrence of prostate cancer. Patients and Methods: Data from 241 patients who had undergone total prostatectomy between 2007 and 2011 were used. EPHA2 protein expression was categorized as high or low by two pathologists. The relationship was examined between EPHA2 expression level (high vs. low) and clinicopathological factors including biochemical recurrence. Correlations were examined between EPHA2, low-molecular-weight protein tyrosine phosphatase (LMW-PTP), E-cadherin, and Ki-67. Results: EPHA2 expression was high in 121 (50.2%) and low in 120 (49.8%) patients. A log-rank test revealed early biochemical recurrence in the high-expression group. Gleason score, Ki-67 labeling index, and biochemical recurrence were more frequent in the high-expression group. Furthermore, multivariate analyses revealed that high EPHA2 expression was an independent prognostic factor for biochemical recurrence (hazard ratio=3.62, 95% confidence interval=2.39-5.61). Correlations between EPHA2 and both LMW-PTP and Ki-67 labeling index were positive, whereas EPHA2 and E-cadherin were negatively correlated. Conclusion: EPHA2 overexpression is predictive of aggressive prostate cancer behavior. EPHA2 may be a powerful prognostic biomarker for decision-making in postoperative follow-up after total prostatectomy, and regarding the need for palliative treatment. Additionally, it may be an important therapeutic target.

[1]  J. Akiba,et al.  Low-molecular-weight Protein Tyrosine Phosphatase Is a Possible Biomarker for Predicting Postoperative Biochemical Recurrence in Prostate Cancer With Negative Surgical Margins , 2019, AntiCancer Research.

[2]  J. Akiba,et al.  High sulfite oxidase expression could predict postoperative biochemical recurrence in patients with prostate cancer , 2019, Medical Molecular Morphology.

[3]  Kazunori Kato,et al.  An Agonistic Antibody to EPHA2 Exhibits Antitumor Effects on Human Melanoma Cells , 2018, AntiCancer Research.

[4]  K. Kuroiwa,et al.  Predictive factors of late biochemical recurrence after radical prostatectomy , 2017, Japanese journal of clinical oncology.

[5]  B. Tombal,et al.  Predictive factors associated with biochemical recurrence following radical prostatectomy for pathological T2 prostate cancer with negative surgical margins , 2017, Scandinavian journal of urology.

[6]  Jin-cheng Pan,et al.  Vasculogenic Mimicry in Prostate Cancer: The Roles of EphA2 and PI3K , 2016, Journal of Cancer.

[7]  S. Batra,et al.  ErbB-2 signaling plays a critical role in regulating androgen-sensitive and castration-resistant androgen receptor-positive prostate cancer cells. , 2015, Cellular signalling.

[8]  Maria Rosestedt,et al.  Imaging of HER2 may improve the outcome of external irradiation therapy for prostate cancer patients , 2014, Oncology letters.

[9]  Y. Goldgur,et al.  Generation and characterization of a single-chain anti-EphA2 antibody , 2014, Growth factors.

[10]  B. Zhang,et al.  EphA2 enhances the proliferation and invasion ability of LNCaP prostate cancer cells , 2014, Oncology letters.

[11]  Markus Graefen,et al.  Positive surgical margins after radical prostatectomy: a systematic review and contemporary update. , 2014, European urology.

[12]  S. Byun,et al.  The prognostic value of pathologic prostate-specific antigen mass ratio in patients with localized prostate cancer with negative surgical resection margins. , 2013, Urology.

[13]  L. Costa,et al.  Low Molecular Weight Protein Tyrosine Phosphatase Isoforms Regulate Breast Cancer Cells Migration through a RhoA Dependent Mechanism , 2013, PloS one.

[14]  W. Lowrance,et al.  Contemporary open and robotic radical prostatectomy practice patterns among urologists in the United States. , 2012, The Journal of urology.

[15]  Jim Manavis,et al.  Automatic Nonsubjective Estimation of Antigen Content Visualized by Immunohistochemistry Using Color Deconvolution , 2012, Applied immunohistochemistry & molecular morphology : AIMM.

[16]  T. Yokoi,et al.  Significant prognostic factor of immunohistochemical HER‐2 expression using initial prostate biopsy specimens with M1b prostate cancer , 2011, The Prostate.

[17]  A. Haese*,et al.  Biochemical recurrence after radical prostatectomy: multiplicative interaction between surgical margin status and pathological stage. , 2010, The Journal of urology.

[18]  P. Humphrey,et al.  The Gleason Score of Tumor at the Margin in Radical Prostatectomy is Predictive of Biochemical Recurrence , 2010, The American journal of surgical pathology.

[19]  Xianwei Wang,et al.  Expression of EphA2 and E-cadherin in Gastric Cancer: Correlated with Tumor Progression and Lymphogenous Metastasis , 2009, Pathology & Oncology Research.

[20]  K. Flaherty,et al.  Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide. , 2009, The Journal of investigative dermatology.

[21]  M. Peppelenbosch,et al.  From immune response to cancer: a spot on the low molecular weight protein tyrosine phosphatase , 2009, Cellular and Molecular Life Sciences.

[22]  J. Fletcher,et al.  Imatinib Targeting of KIT-Mutant Oncoprotein in Melanoma , 2008, Clinical Cancer Research.

[23]  K. Flaherty,et al.  Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells. , 2008, The Journal of investigative dermatology.

[24]  Jin Chen,et al.  Overexpression of EPHA2 receptor destabilizes adherens junctions via a RhoA-dependent mechanism , 2008, Journal of Cell Science.

[25]  M. Kattan,et al.  Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens. , 2005, The Journal of urology.

[26]  R. Bristow,et al.  Optimal treatment of intermediate‐risk prostate carcinoma with radiotherapy , 2005, Cancer.

[27]  Elena B. Pasquale,et al.  Developmental cell biology: Eph receptor signalling casts a wide net on cell behaviour , 2005, Nature Reviews Molecular Cell Biology.

[28]  P. Walsh,et al.  Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. , 2005, The Journal of urology.

[29]  A. Sood,et al.  EphA2 Expression Is Associated with Aggressive Features in Ovarian Carcinoma , 2004, Clinical Cancer Research.

[30]  M. Kattan,et al.  Predicting the presence and side of extracapsular extension: a nomogram for staging prostate cancer. , 2004, The Journal of urology.

[31]  Dana M. Brantley-Sieders,et al.  EphA2 receptor tyrosine kinase regulates endothelial cell migration and vascular assembly through phosphoinositide 3-kinase-mediated Rac1 GTPase activation , 2004, Journal of Cell Science.

[32]  E. B. Butler,et al.  Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. , 2004, JAMA.

[33]  H. Kuwano,et al.  Expression of EphA2 and E-cadherin in colorectal cancer: correlation with cancer metastasis. , 2004, Oncology Report.

[34]  C. Dinney,et al.  Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family. , 2003, Critical reviews in oncology/hematology.

[35]  K. Nakagawa,et al.  Prediction of extraprostatic cancer by prostate specific antigen density, endorectal MRI, and biopsy Gleason score in clinically localized prostate cancer , 2003, The Prostate.

[36]  M. Kinch,et al.  EphA2 overexpression decreases estrogen dependence and tamoxifen sensitivity. , 2003, Cancer research.

[37]  F. Saad,et al.  Digital rectal exam following prostatectomy: is it still necessary with the use of PSA? , 2003, European urology.

[38]  H. Kuwano,et al.  EphA2 overexpression correlates with poor prognosis in esophageal squamous cell carcinoma , 2003, International journal of cancer.

[39]  D. Harpole,et al.  Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[40]  M. Kinch,et al.  Regulation of the EphA2 Kinase by the Low Molecular Weight Tyrosine Phosphatase Induces Transformation* , 2002, The Journal of Biological Chemistry.

[41]  Michael W Kattan,et al.  Cancer control with radical prostatectomy alone in 1,000 consecutive patients. , 2002, The Journal of urology.

[42]  M. Hendrix,et al.  Molecular regulation of tumor cell vasculogenic mimicry by tyrosine phosphorylation: role of epithelial cell kinase (Eck/EphA2). , 2001, Cancer research.

[43]  M. Kinch,et al.  EphA2 overexpression causes tumorigenesis of mammary epithelial cells. , 2001, Cancer research.

[44]  D. Bennett,et al.  Protein tyrosine kinases in malignant melanoma. , 2000, Melanoma research.

[45]  D. Bostwick,et al.  Overexpression of the EphA2 tyrosine kinase in prostate cancer , 1999, The Prostate.

[46]  A. Partin,et al.  Digital rectal examination and imaging studies are unnecessary in men with undetectable prostate specific antigen following radical prostatectomy. , 1999, The Journal of urology.

[47]  M. Kinch,et al.  E-cadherin regulates the function of the EphA2 receptor tyrosine kinase. , 1999, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[48]  S B Malkowicz,et al.  Biochemical Outcome After Radical Prostatectomy , External Beam Radiation Therapy , or Interstitial Radiation Therapy for Clinically Localized Prostate Cancer , 2000 .

[49]  M. Göke,et al.  Epithelial cell kinase-B61: an autocrine loop modulating intestinal epithelial migration and barrier function. , 1997, American journal of physiology. Gastrointestinal and liver physiology.

[50]  J. Biegel,et al.  ECK, a human EPH-related gene, maps to 1p36.1, a common region of alteration in human cancers. , 1997, Genomics.

[51]  M. Herlyn,et al.  Protein B61 as a new growth factor: expression of B61 and up-regulation of its receptor epithelial cell kinase during melanoma progression. , 1995, Cancer research.

[52]  T. Hunter,et al.  cDNA cloning and characterization of eck, an epithelial cell receptor protein-tyrosine kinase in the eph/elk family of protein kinases , 1990, Molecular and cellular biology.

[53]  Liang Cheng,et al.  Expression of EphA 2 and Ephrin A-1 in Carcinoma of the Urinary Bladder , 2006 .

[54]  M. Kinch,et al.  Overexpression and functional alterations of the EphA2 tyrosine kinase in cancer , 2004, Clinical & Experimental Metastasis.